Finally, the incidence figures of these three studies are overstated in part due to use of delivery and maternity denominators in patients with PASS DNA Damage inhibitor in the context of all pregnancy outcomes (i.e., abortion), rather than the total number of pregnancies among women at risk during study period. Table 1 Key characteristics of studies providing epidemiological data on pregnancy-associated severe sepsis References Years of study Type/Country Number of patients Scope of pregnancy outcomes Mabie et al. [27] 1986–1997 Local/US 18 All Waterstone et al. [28] 1997–1998

Regional/UK 17 All deliveries after 24 weeks of gestation Acosta et al. [29] 1986–2008 Local/UK 14 All Kramer et al. [30] 2004–2006 National/Netherlands 78 All Acosta et al. [32] 2005–2007 State/US 791a Live birth hospitalizations Bauer et al. [33] 1998–2008 National/US 4,158a Delivery hospitalizations UK United Kingdom, US United States aNumber of hospitalizations Three population-level studies on PASS have been recently reported. Kramer et al. [30] have performed a retrospective analysis of a prospective national cohort in the Netherlands on severe maternal morbidity. The incidence of PASS was 21 per 100,000 deliveries-years. However, the validity of this estimate is Selleck Verubecestat limited by numerous methodological {Selleck Anti-infection Compound Library|Selleck Antiinfection Compound Library|Selleck Anti-infection Compound Library|Selleck Antiinfection Compound Library|Selleckchem Anti-infection Compound Library|Selleckchem Antiinfection Compound Library|Selleckchem Anti-infection Compound Library|Selleckchem Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|buy Anti-infection Compound Library|Anti-infection Compound Library ic50|Anti-infection Compound Library price|Anti-infection Compound Library cost|Anti-infection Compound Library solubility dmso|Anti-infection Compound Library purchase|Anti-infection Compound Library manufacturer|Anti-infection Compound Library research buy|Anti-infection Compound Library order|Anti-infection Compound Library mouse|Anti-infection Compound Library chemical structure|Anti-infection Compound Library mw|Anti-infection Compound Library molecular weight|Anti-infection Compound Library datasheet|Anti-infection Compound Library supplier|Anti-infection Compound Library in vitro|Anti-infection Compound Library cell line|Anti-infection Compound Library concentration|Anti-infection Compound Library nmr|Anti-infection Compound Library in vivo|Anti-infection Compound Library clinical trial|Anti-infection Compound Library cell assay|Anti-infection Compound Library screening|Anti-infection Compound Library high throughput|buy Antiinfection Compound Library|Antiinfection Compound Library ic50|Antiinfection Compound Library price|Antiinfection Compound Library cost|Antiinfection Compound Library solubility dmso|Antiinfection Compound Library purchase|Antiinfection Compound Library manufacturer|Antiinfection Compound Library research buy|Antiinfection Compound Library order|Antiinfection Compound Library chemical structure|Antiinfection Compound Library datasheet|Antiinfection Compound Library supplier|Antiinfection Compound Library in vitro|Antiinfection Compound Library cell line|Antiinfection Compound Library concentration|Antiinfection Compound Library clinical trial|Antiinfection Compound Library cell assay|Antiinfection Compound Library screening|Antiinfection Compound Library high throughput|Anti-infection Compound high throughput screening| problems. There has been no explicit definition of sepsis, and severe

sepsis was defined in part by admission to an ICU or any case of (an undefined) sepsis a physician considered to be severe morbidity. Specific OF/dysfunction criteria were not used, which may have led to misclassification and overestimation of PASS incidence, as not all ICU admissions with an ifoxetine infection are due to severe sepsis. Indeed, as noted in a report by Afessa et al. [31], studying obstetric patients in the ICU, among all obstetric sepsis

patients admitted to the ICU, 49% did not have severe sepsis, when the authors used the consensus definitions [1]. In addition, as acknowledged by the investigators, sepsis was not a pre-defined condition for the prospective data collection, leading to possible underestimation of PASS events [30]. The number of PASS patients was only 78, limiting further the precision of incidence estimates. Finally, although PASS events spread over all pregnancy outcomes, the denominator used for incidence estimates was the number of deliveries which, as noted above, may have overestimated the actual incidence. A more recent study by Acosta et al. [32] examined administrative data of live birth hospitalizations in the state of California. The reported incidence of PASS was 49 hospitalizations per 100,000 live births-years. The investigators included hospital length of stay ≥90th percentile and/or admission to ICU as part of case definition of severe sepsis, while not including OF criteria.